Relmada Therapeutics, Inc. (RLMD) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
7/25
Growth 2
Margin 0
Expansion 3
Platform 0
Financial 2
latest quarter score
Earnings Reports
- 7
- 9
- 8
- 8
- 8
- 6
- 9